Lung Cancer

A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.

The first-line combination of sintilimab injection plus pemetrexed and platinum-based therapy showed a statistically significant improvement in progression-free survival compared with chemotherapy and placebo in patients with advanced or recurrent nonsquamous non–small cell lung cancer who did not harbor EGFR or ALK abnormalities, according to an interim analysis of the phase III ORIENT-11 trial.

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

During an OncLive Peer Exchange program, an international panel of lung cancer experts provided perspective on key findings regarding various immune checkpoint inhibitor (ICI) combinations and data concerning potential biomarkers of response to ICIs in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

The combination of pembrolizumab and chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with extensive-stage small cell lung cancer.

Kaushal Parikh, MD, MBBS, reflects on pivotal lung cancer data shared at recent major oncology meetings.